Characterization and analysis of the aggregation of a singlechain chimeric Anti-ErbB2 antibody

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 24, Issue 11, 2008, Pages 1918-1923

  Zhu, Juanjuan ^a   Rong, Ziye ^a   Jiang, Bing ^a   Liu, Jing ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Aggregation; Chimeric antibody; Circular dichroism; Dynamic light scattering

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT PROTEIN;

ARTICLE; BIOSYNTHESIS; CAPPING PHENOMENON; CHEMISTRY; GENETICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; METHODOLOGY; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

ANTIBODIES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECEPTOR AGGREGATION; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS;

EID: 70349331038     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Moore JM, Patapoff TW, Cromwell ME. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry, 1999, 38(42): 13960-13967.
2. Andya JD, Hsu CC, Shire SJ. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci, 2003, 5(2): 1-11.
3. Wu AM, Tan GJ, Sherman MA, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng, 2001, 14(12): 1025-1033.
4. Kameoka D, Masuzaki E, Ueda T, et al. Effect of buffer species on the unfolding and the aggregation of humanized IgG. J Biochem, 2007, 142(3): 383-391.
5. Wang W, Singh S, Zeng DL, et al. Antibody structure, instability, and formulation. J Pharm Sci, 2007, 96(1): 1-26.
6. Cheng LS, Liu AP, Yang JH, et al. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185 (c-erbB-2). Cell Res, 2003, 13(1): 35-48.
7. Wang J, Shi Y, Liu YQ, et al. Purification characterization of a single-chain chimeric anti-p185 antibody expressed by CHO-GS system. Protein Expr Purif, 2005, 41(1): 68-76.
8. Hu SY, Zhu ZQ, Li LW, et al. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins, 2008, 70(3): 938-949.
9. Ma J, Dong YQ, Zou M, et al. Effect of sodium butyrate and propionate on cell growth, metabolism and expression of the chimeric antibody. China Biotechnol, 2005, 25(10): 12-16.
10. Qiao JJ, Liu HB, Zhu JJ, et al. The research on expression and purification of chimeric anti-P185 antibody. China Biotechnol, 2006, 26(9): 32-37.
11. Bermudez O, Forciniti D. Aggregation and denaturation of antibodies: a capillary electrophoresis, dynamic light scattering, and aqueous two-phase partitioning study. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 807(1): 17-24.
12. Ejima D, Tsumoto K, Fukada H, et al. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins, 2007, 66(4): 954-962.
13. Hugo N, Lafont V, Beukes M, et al. Functional aspects of co-variant surface charges in an antibody fragment. Protein Sci, 2002, 11(11): 2697-2705.
14. Ahrer K, Buchacher A, Iberer G, et al. Thermodynamic stability and formation of aggregates of human immunoglobulin G characterised by differential scanning calorimetry and dynamic light scattering. J Biochem Biophys Methods, 2006, 66(1-3): 73-86.
15. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci, 2004, 93(6): 1390-1402.
16. Arndt KM, Muller KM, Pluckthun A. Factors influencing the dimer to monomer transition of an antibody single- chain Fv fragment. Biochemistry, 1998, 37(37): 12918-12926.